Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 12 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-8.03 Insider Own5.79% Shs Outstand90.57M Perf Week10.42%
Market Cap4.09B Forward P/E- EPS next Y-5.18 Insider Trans-1.53% Shs Float85.33M Perf Month9.03%
Income-613.35M PEG- EPS next Q-1.67 Inst Own89.68% Short Float4.96% Perf Quarter-10.97%
Sales442.59M P/S9.24 EPS this Y19.25% Inst Trans-2.79% Short Ratio4.72 Perf Half Y-4.28%
Book/sh1.69 P/B26.74 EPS next Y22.26% ROA-45.59% Short Interest4.24M Perf Year2.71%
Cash/sh4.62 P/C9.77 EPS next 5Y37.90% ROE-340.05% 52W Range31.52 - 54.56 Perf YTD-5.60%
Dividend Est.- P/FCF- EPS past 5Y-15.75% ROI-60.31% 52W High-17.27% Beta0.56
Dividend TTM- Quick Ratio2.28 Sales past 5Y63.06% Gross Margin86.59% 52W Low43.21% ATR (14)1.62
Dividend Ex-Date- Current Ratio2.43 EPS Y/Y TTM21.74% Oper. Margin-131.15% RSI (14)66.39 Volatility3.43% 4.15%
Employees1276 Debt/Eq6.65 Sales Y/Y TTM15.29% Profit Margin-138.58% Recom1.20 Target Price90.35
Option/ShortYes / Yes LT Debt/Eq6.25 EPS Q/Q13.10% Payout- Rel Volume1.48 Prev Close43.89
Sales Surprise-6.20% EPS Surprise-16.19% Sales Q/Q8.30% EarningsMay 02 AMC Avg Volume896.46K Price45.14
SMA2010.47% SMA509.83% SMA2005.90% Trades Volume1,327,477 Change2.85%
Date Action Analyst Rating Change Price Target Change
Jun-06-24Upgrade Goldman Neutral → Buy $56 → $67
Apr-22-24Initiated RBC Capital Mkts Outperform $77
Dec-08-23Initiated Wells Fargo Overweight $72
Jun-14-23Resumed Credit Suisse Outperform $96
Jun-06-23Upgrade Evercore ISI In-line → Outperform $60 → $80
Apr-26-23Initiated Cantor Fitzgerald Overweight $114
Jan-18-23Resumed Canaccord Genuity Buy $90
Dec-30-22Resumed H.C. Wainwright Buy $82
Nov-03-22Upgrade Robert W. Baird Neutral → Outperform $50
Oct-13-22Upgrade Guggenheim Neutral → Buy $50
Jun-20-24 04:30PM
Jun-17-24 03:27PM
Jun-13-24 08:49PM
03:14AM Loading…
Jun-12-24 04:05PM
Jun-11-24 05:47PM
Jun-04-24 04:05PM
May-31-24 10:36AM
May-30-24 04:00PM
May-22-24 02:27PM
04:30PM Loading…
May-17-24 04:30PM
May-07-24 04:30PM
May-04-24 10:24AM
May-03-24 03:01PM
May-02-24 08:58PM
Apr-30-24 04:00PM
Apr-25-24 04:30PM
Apr-19-24 04:30PM
11:33AM Loading…
Apr-16-24 11:33AM
Apr-15-24 07:30AM
Apr-12-24 04:22PM
Mar-22-24 04:00PM
Mar-20-24 08:11AM
Mar-12-24 05:00PM
Mar-11-24 03:00PM
Mar-08-24 09:38AM
Feb-27-24 04:30PM
Feb-23-24 04:05PM
Feb-16-24 10:43AM
Feb-15-24 04:15PM
Feb-13-24 01:36PM
Feb-08-24 04:00PM
Feb-06-24 08:00AM
Feb-05-24 04:05PM
Jan-25-24 04:05PM
Jan-19-24 04:00PM
Jan-18-24 02:41PM
Jan-09-24 06:20PM
Jan-08-24 12:18PM
Jan-07-24 11:00AM
Jan-04-24 08:12AM
Jan-03-24 08:00AM
Jan-02-24 04:05PM
Dec-27-23 06:41PM
Dec-21-23 05:21PM
Dec-18-23 09:29AM
Dec-15-23 10:18AM
Nov-20-23 04:30PM
Nov-17-23 04:30PM
Nov-07-23 05:00PM
Nov-04-23 01:12PM
Nov-03-23 11:43AM
Nov-02-23 06:26PM
Oct-26-23 04:05PM
Oct-25-23 06:17AM
Oct-23-23 04:01PM
Oct-20-23 04:00PM
Oct-18-23 09:16PM
Oct-17-23 04:02PM
Oct-16-23 08:00AM
Oct-14-23 04:30PM
Oct-12-23 05:00PM
Oct-09-23 08:00AM
Oct-05-23 08:00AM
Sep-25-23 05:13PM
Sep-20-23 05:00PM
Sep-07-23 12:36PM
Aug-31-23 09:00AM
Aug-18-23 05:00PM
Aug-12-23 11:05AM
Aug-11-23 11:14AM
Aug-10-23 06:27PM
Aug-08-23 07:11AM
Aug-04-23 08:34AM
Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanders Corazon (Corsee) D.DirectorJul 02 '24Sale40.9858423,93212,009Jul 03 02:07 PM
Parschauer Karah HerdmanEVP and Chief Legal OfficerJun 12 '24Sale45.009,806441,27057,981Jun 12 07:47 PM
Sanders Corazon (Corsee) D.DirectorJun 10 '24Sale41.101,73771,3917,248Jun 10 07:58 PM
Crombez EricEVP and Chief Medical OfficerMay 02 '24Sale43.6635415,45648,431May 03 03:23 PM
Crombez EricEVP and Chief Medical OfficerApr 18 '24Sale44.101426,26248,785Apr 19 04:35 PM
Kassberg Thomas RichardCBO & EVPMar 11 '24Sale49.9311,509574,644252,823Mar 12 01:41 PM
Fust Matthew KDirectorMar 07 '24Sale50.8812,195620,44314,860Mar 11 12:54 PM
Harris ErikEVP & Chief Commercial OfficerMar 01 '24Sale53.764,768256,32867,163Mar 05 08:08 PM
Pinion John RichardSee RemarksMar 01 '24Sale53.764,173224,34089,268Mar 05 08:15 PM
Parschauer Karah HerdmanEVP and Chief Legal OfficerMar 01 '24Sale53.763,756201,92367,340Mar 05 08:22 PM
Crombez EricEVP and Chief Medical OfficerMar 01 '24Sale53.761,23866,55548,927Mar 05 08:10 PM
Kassberg Thomas RichardCBO & EVPMar 01 '24Sale53.761,01154,351264,332Mar 05 08:19 PM
Huizenga Theodore AlanSVP, Chief Accounting OfficerMar 01 '24Sale53.7634118,33241,380Mar 05 08:13 PM
KAKKIS EMIL DPresident & CEOFeb 07 '24Sale45.0030,0001,350,000539,770Feb 08 03:49 PM
Huizenga Theodore AlanSVP, Chief Accounting OfficerJan 02 '24Option Exercise21.003,00063,00027,892Jan 02 04:06 PM
KAKKIS EMIL DPresident & CEODec 29 '23Sale47.8730,0001,436,100569,770Jan 02 04:07 PM
Kassberg Thomas RichardCBO & EVPOct 23 '23Option Exercise6.8639,878273,563286,738Oct 24 05:22 PM
Kassberg Thomas RichardCBO & EVPOct 23 '23Sale32.7839,8781,307,201246,860Oct 24 05:22 PM
KAKKIS EMIL DPresident & CEOOct 19 '23Option Exercise6.8647,853328,272647,029Oct 23 05:14 PM
KAKKIS EMIL DPresident & CEOOct 19 '23Sale33.5247,8531,604,033599,743Oct 23 05:14 PM
Huizenga Theodore AlanSVP, Chief Accounting OfficerSep 07 '23Option Exercise21.002,00042,00025,777Sep 11 01:52 PM
Huizenga Theodore AlanSVP, Chief Accounting OfficerSep 07 '23Sale40.802,16388,24923,614Sep 11 01:52 PM
Harris ErikEVP & Chief Commercial OfficerSep 05 '23Sale37.966,000227,76051,281Sep 06 05:51 PM
Huizenga Theodore AlanSVP, Chief Accounting OfficerSep 01 '23Sale37.1597036,03223,777Sep 06 05:50 PM